Taxane-associated dysgeusia Signs and Symptoms Dysgeusia
Conditions
Interventions
The participants were randomly allocated to the following two arms:
Intervention arm: Glutamine (oral) 30 g per day in 2-3 doses
Control arm: Maltodextrin (as placebo)
Sponsors
Cantonal Hospital St.Gallen (Switzerland)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult patients with cancer receiving for the first time a taxane-containing chemotherapy 2. Written informed consent 3. Able to feed themselves 4. Eastern Cooperative Oncology Group (ECOG) PS 2 or less
Exclusion criteria
Exclusion criteria: 1. Previous surgery or radiotherapy of the oral or nasal region 2. Oral candidiasis 3. Zinc deficiency 4. Creatinine clearance of greater than or equal to 30 ml/min
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Taste alteration (dysgeusia), reported daily by the patient at the same time of the day (usually before dinner) answering the question ?Presently my sense of taste is ...? using a Visual Analogue Scale (VAS: 0 mm = very good; 100 mm = very bad). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Taste recognition test, carried out at baseline, on day one of each chemotherapy cycle, and in addition on day 8 of the second chemotherapy cycle. 2. Adverse events | — |
Countries
Switzerland
Outcome results
None listed